Ea Pharma Co., Ltd.

Atsushi Tsuruta

Kenji Asano

Munetaka Tokumasu

Wataru Miyanaga

Misato Noguchi

Ayatoshi Ando

Yuki Saitou

Nobuhiko Hayakawa

Toshiyuki Takanohashi

Masatsugu Noguchi

Kazuo Kuyama

Yui Yamaura

Mizuki Kawahira

Daisuke Kataoka

Hirotaka Wagatsuma

Kana Iwasaki

A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof, or a solvate of the same which is to be administered by a predefined route in a predefined dosage. According to the present invention, it is possible to provide a prophylactic or therapeutic agent for secondary hyperparathyroidism under maintenance dialysis, said agent showing reduced side effects or no significant accumulation. This medicinal agent allows easy administration management and has a high safety compared with conventional products.

Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis

Provided is a compound having &#x3b1;4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where Rto R, e to h, D, and B represent those as described in the specification.

Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

Growing community of inventors

Kanagawa, Japan

Atsushi Tsuruta